Assigment .Apa seven . All instructions attached.
butterflyl
ReferencesArticle1.pdf
1. Ahmed, F., Gaul, C., & Sommer, K. (2022). Real-world safety and efficacy of 156–195
U onabotulinumtoxinA in participants with chronic migraine: Results from the REPOSE
study. Toxicon, 214, S3–S4. https://doi.org/10.1016/j.toxicon.2021.11.016
2. Ahmed, F., Gaul, C., Kollewe, K., Singh, R. C., & Sommer, K. (2025). Real-world safety
and efficacy of 156–195 U onabotulinumtoxinA in adults with chronic migraine: Results
from the REPOSE study. BMC Neurology, 25, 197–211.
3. Algahtani, H., Shirah, B., Sukkar, G., Bukhari, H., Meftah, I., Alhazmi, A., Alshareef, A.,
Algethami, A., Alshanqiti, A., & Andeejani, M. (2021). Botulinum toxin injection in the
management of chronic migraine: The Saudi experience with a proposal for a new
protocol. Acta Neurologica Belgica, 121(6), 1783–1787. https://doi.org/10.1007/s13760-
020-01521-0
4. Altamura, C., Brunelli, N., Viticchi, G., Salvemini, S., Cecchi, G., Marcosano, M., Fofi,
L., Silvestrini, M., & Vernieri, F. (2023). Quantitative and qualitative pain evaluation in
response to onabotulinumtoxinA for chronic migraine: An observational real-life study.
Toxins, 15(4), 284. https://doi.org/10.3390/toxins15040284
5. Altamura, C., Ornello, R., Ahmed, F., Negro, A., Miscio, A. M., Santoro, A., Alpuente,
A., Russo, A., Silvestro, M., Cevoli, S., Brunelli, N., Grazzi, L., Baraldi, C., Guerzoni, S.,
Andreou, A. P., Lambru, G., Frattale, I., Kamm, K., Ruscheweyh, R., & Vernieri, F.
(2023). OnabotulinumtoxinA in elderly patients with chronic migraine: Insights from a
real-life European multicenter study. Journal of Neurology, 270(2), 986–994.
https://doi.org/10.1007/s00415-022-11457-5
6. Armanious, M., Khalil, N., Lu, Y., & Jimenez-Sanders, R. (2021). Erenumab and
onabotulinumtoxinA combination therapy for the prevention of intractable chronic
migraine without aura: A retrospective analysis. Journal of Pain & Palliative Care
Pharmacotherapy, 35(1), 1–6. https://doi.org/10.1080/15360288.2020.1829249
7. Argyriou, A. A., Dermitzakis, E. V., Chondrogianni, M., Foska, A., Rikos, D.,
Xiromerisiou, G., Soldatos, P., Litsardopoulos, P., & Vikelis, M. (2025).
OnabotulinumtoxinA to prevent chronic migraine with comorbid bruxism: Real-world
data from the GRASP study group. Toxins, 17(11), 547.
https://doi.org/10.3390/toxins17110547
8. Argyriou, A. A., Dermitzakis, E. V., Rikos, D., Xiromerisiou, G., Soldatos, P.,
Litsardopoulos, P., & Vikelis, M. (2024). Effects of onabotulinumtoxinA on allodynia
and interictal burden of patients with chronic migraine. Toxins, 16(2), 106.
https://doi.org/10.3390/toxins16020106
9. Argyriou, A. A., Dermitzakis, E. V., Vlachos, G. S., & Vikelis, M. (2022). Long-term
adherence, safety, and efficacy of repeated onabotulinumtoxinA over five years in
chronic migraine prophylaxis. Acta Neurologica Scandinavica, 145(6), 676–683.
https://doi.org/10.1111/ane.13600
10. Argyriou, A. A., Dermitzakis, E. V., Xiromerisiou, G., & Vikelis, M. (2022).
OnabotulinumtoxinA add-on to monoclonal anti-CGRP antibodies in treatment-refractory
chronic migraine. Toxins, 14(12), 847. https://doi.org/10.3390/toxins14120847
11. Atraszkiewicz, D. (2021). The processes underlying chronic migraine pathophysiology
and its treatment with botulinum toxin type A. Neurology and Clinical Neuroscience,
9(6), 421–429. https://doi.org/10.1111/ncn3.12551
12. Baraldi, C., Lo Castro, F., Ornello, R., Sacco, S., Pani, L., & Guerzoni, S. (2023).
OnabotulinumtoxinA: Still the present for chronic migraine. Toxins, 15(1), 59.
https://doi.org/10.3390/toxins15010059
13. Becker, W. J., Boudreau, G., Finkelstein, I., Graboski, C., Ong, M., Christie, S., Sommer,
K., Bhogal, M., & Davidovic, G. (2023). OnabotulinumtoxinA reduces health resource
utilization in chronic migraine: The PREDICT study. Canadian Journal of Neurological
Sciences.
14. Blumenfeld, A. M., Mechtler, L., Cook, L., Rhyne, C., Jenkins, B., Hughes, O.,
Dabruzzo, B., Manack Adams, A., & Diamond, M. (2024). Real-world evidence of the
safety and effectiveness of atogepant added to onabotulinumtoxinA for the preventive
treatment of chronic migraine: A retrospective chart review. Pain and Therapy, 13(6),
1571–1587. https://doi.org/10.1007/s40122-024-00649-8
15. Boczarska-Jedynak, M. (2023). Experience of treatment of chronic migraine with
botulinum toxin type A among aesthetic medicine professionals in Poland. Neurologia i
Neurochirurgia Polska, 57(4), 363–370. https://doi.org/10.5603/PJNNS.a2023.0049
16. Boczarska-Jedynak, M., Bott-Karoń, M., Marschollek, K., Antolak, M., Świat, M., &
Waliszewska-Prosół, M. (2025). Patient satisfaction with aesthetic outcomes following
onabotulinumtoxinA treatment for chronic migraine: A cross-sectional study. Toxins,
17(6), 292. https://doi.org/10.3390/toxins17060292
17. Boudreau, G., Finkelstein, I., Graboski, C., Ong, M., Christie, S., Sommer, K., Bhogal,
M., Davidovic, G., & Becker, W. J. (2022). OnabotulinumtoxinA improves quality of life
in chronic migraine: The PREDICT study. Canadian Journal of Neurological Sciences,
49(4), 540–552. https://doi.org/10.1017/cjn.2021.153
18. Boudreau, G., Finkelstein, I., Graboski, C., Ong, M., Christie, S., Sommer, K., Bhogal,
M., Davidovic, G., & Becker, W. J. (2024). OnabotulinumtoxinA improves quality of life
in chronic migraine: The PREDICT study – Corrigendum. Canadian Journal of
Neurological Sciences, 51(1), 149–149. https://doi.org/10.1017/cjn.2023.317
19. Chan, T. L. H. (2022). OnabotulinumtoxinA improves quality of life in chronic migraine:
The PREDICT study. Canadian Journal of Neurological Sciences, 49(4), 477–478.
https://doi.org/10.1017/cjn.2021.159
20. Cheema, S., Lagrata, S., Rantell, K. R., Ahmed, M., Kamourieh, S., & Matharu, M. S.
(2025). OnabotulinumtoxinA for primary new daily persistent headache and comparison
to chronic migraine. Cephalalgia, 45(2), 3331024251317448.
https://doi.org/10.1177/03331024251317448
21. Diener, H., Dodick, D. W., Lipton, R. B., Sommer, K., & Silberstein, S. D. (2022).
Consecutive headache-free days with onabotulinumtoxinA treatment in patients with
chronic migraine: A pooled PREEMPT analysis. Toxicon, 214, S15–S16.
https://doi.org/10.1016/j.toxicon.2021.11.043
22. Drellia, K., Kokoti, L., Deligianni, C. I., Papadopoulos, D., & Mitsikostas, D. D. (2021).
Anti-CGRP monoclonal antibodies for migraine prevention: A systematic review and
likelihood to help or harm analysis. Cephalalgia, 41(7), 851–864.
https://doi.org/10.1177/0333102421989601
23. Ermanis, G., Tereshko, Y., Belgrado, E., Lettieri, C., Gigli, G. L., & Valente, M. (2025).
Botulinum toxin as an effective rescue treatment after failure of anti-CGRP monoclonal
antibodies in chronic migraine patients. Toxicon, 268, 108605.
https://doi.org/10.1016/j.toxicon.2025.108605
24. Ferlisi, S., Di Marco, S., Pilati, L., Torrente, A., Scardina, S., Di Marco, E., La Bianca,
G., Cosentino, G., & Brighina, F. (2021). Onabotulinumtoxina reduce visual cortical
excitability in chronic migraine: Preliminary results of a study with sound-induced flash
illusions. Journal of the Neurological Sciences, 429, 119262.
https://doi.org/10.1016/j.jns.2021.119262
25. Frank, F., Ulmer, H., Sidoroff, V., & Broessner, G. (2021). CGRP-antibodies, topiramate
and botulinum toxin type A in episodic and chronic migraine: A systematic review and
meta-analysis. Cephalalgia, 41(11–12), 1222–1239.
https://doi.org/10.1177/03331024211018137
26. Gaviria, E., & Eltayeb Hamid, A. H. (2024). Comparative long-term effectiveness of
onabotulinumtoxinA and anti-CGRP therapies in migraine prevention: A systematic
review. F1000Research, 13, 665. https://doi.org/10.12688/f1000research.151605.1
27. Gómez-Dabó, L., Caronna, E., Mas-de-les-Valls, R., Gallardo, V. J., Alpuente, A.,
Torres-Ferrus, M., & Pozo-Rosich, P. (2024). Effectiveness and safety of
onabotulinumtoxinA in adolescent patients with chronic migraine. Toxins, 16(5), 221.
https://doi.org/10.3390/toxins16050221
28. Grazzi, L., Giossi, R., Montisano, D. A., Canella, M., Marcosano, M., Altamura, C., &
Vernieri, F. (2024). Real-world effectiveness of anti-CGRP monoclonal antibodies
compared to onabotulinumtoxinA (RAMO study). Journal of Headache and Pain, 25, 14.
https://doi.org/10.1186/s10194-024-01721-6
29. Grazzi, L., Montisano, D. A., Rizzoli, P., Guastafierro, E., Marcassoli, A., Fornari, A., &
Raggi, A. (2023). A single-group study on the effect of onabotulinumtoxinA in patients
with chronic migraine associated with medication overuse headache: Pain catastrophizing
plays a role. Toxins, 15(2), 86. https://doi.org/10.3390/toxins15020086
30. Harper, K., Wu, S., Sharp, S., Meystedt, J., Pazira, K., & Charles, D. (2026). Telehealth
follow-up for chronic migraine treated with onabotulinumtoxinA: Patient-reported
satisfaction. Toxicon, 271, 108763. https://doi.org/10.1016/j.toxicon.2025.108763
31. Iannone, L. F., Fattori, D., Marangoni, M., Benemei, S., Chiarugi, A., Geppetti, P., & De
Cesaris, F. (2023). Switching onabotulinumtoxinA to monoclonal anti-CGRP antibodies
in drug-resistant chronic migraine. CNS Drugs, 37(2), 189–202.
https://doi.org/10.1007/s40263-022-00983-5
32. Iannone, L. F., Romozzi, M., Russo, A., Finkelstein, I., Seabi, D., Ahlden, A., Aamodt,
A. H., Caronna, E., Pozo-Rosich, P., Tronvik, E. A., & Sundal, C. (2025). Combination
preventive therapy with onabotulinumtoxinA and atogepant for chronic migraine: The
SYNERGY study. Cephalalgia, 45(12). https://doi.org/10.1177/03331024251398011
33. Jaimes, A., Gómez, A., Pajares, O., & Rodríguez-Vico, J. (2023). Dual therapy with
erenumab and onabotulinumtoxinA: No synergistic effect in chronic migraine: A
retrospective cohort study. Pain Practice, 23(4), 349–358.
https://doi.org/10.1111/papr.13196
34. Karian, V., Morton, H., Schefter, Z. J., Smith, A., Rogan, H., Morse, B., & LeBel, A.
(2023). OnabotulinumtoxinA for pediatric migraine. Pain Management Nursing, 24(6),
610–616. https://doi.org/10.1016/j.pmn.2023.04.006
35. Kępczyńska, K., & Domitrz, I. (2022). Botulinum toxin—A current place in the treatment
of chronic migraine and other primary headaches. Toxins, 14(9), 619.
https://doi.org/10.3390/toxins14090619
36. Kollewe, K., Gaul, C., Gendolla, A., & Sommer, K. (2021). Real-life use of
onabotulinumtoxinA reduces healthcare resource utilization in individuals with chronic
migraine: The REPOSE study. Journal of Headache and Pain, 22(1), 50.
https://doi.org/10.1186/s10194-021-01260-4
37. Lanteri-Minet, M., Ducros, A., Francois, C., Olewinska, E., Nikodem, M., & Dupont-
Benjamin, L. (2022). Effectiveness of onabotulinumtoxinA for preventive treatment of
chronic migraine: A meta-analysis on 10 years of real-world data. Cephalalgia, 42(14),
1543–1564. https://doi.org/10.1177/03331024221123058
38. Lu, J., Zhang, Q., Guo, X., Liu, W., Xu, C., Hu, X., Ni, J., Lu, H., & Zhao, H. (2021).
Calcitonin gene–related peptide monoclonal antibody versus botulinum toxin for the
preventive treatment of chronic migraine. Frontiers in Pharmacology, 12, 631204.
https://doi.org/10.3389/fphar.2021.631204
39. Martínez-Pías, E., Guerrero, Á. L., Sierra, Á., Trigo, J., & García-Azorín, D. (2021).
Daily headache in chronic migraine is a predictive factor of response in patients who had
completed three sessions of onabotulinumtoxinA. Toxins, 13(6), 432.
https://doi.org/10.3390/toxins13060432
40. Mavridi, A., Redmond, A., Archontakis-Barakakis, P., Bogdanova-Mihaylova, P.,
Deligianni, C. I., Mitsikostas, D. D., & Mavridis, T. (2024). OnabotulinumtoxinA in the
prevention of migraine in pediatric populations: A systematic review. Toxins, 16(7), 295.
https://doi.org/10.3390/toxins16070295
41. Moskatel, L. S., Graber-Naidich, A., He, Z., & Zhang, N. (2024). Long-term persistence
to onabotulinumtoxinA to prevent chronic migraine. Pain Medicine, 25(8), 487–492.
https://doi.org/10.1093/pm/pnae020
42. Onan, D., Arıkan, H., & Martelletti, P. (2023). The effect of onabotulinumtoxinA on
headache intensity and number of monthly headache days in individuals with chronic
migraine with different levels of neck disability. Toxins, 15(12), 685.
https://doi.org/10.3390/toxins15120685
43. Onan, D., Bentivegna, E., & Martelletti, P. (2022). OnabotulinumtoxinA treatment in
chronic migraine: Investigation of its effects on disability, headache and neck pain
intensity. Toxins, 15(1), 29. https://doi.org/10.3390/toxins15010029
44. Ornello, R., Ahmed, F., Negro, A., Miscio, A. M., Santoro, A., Alpuente, A., Russo, A.,
Silvestro, M., Cevoli, S., Brunelli, N., Vernieri, F., Grazzi, L., Baraldi, C., Guerzoni, S.,
Andreou, A. P., Lambru, G., Kamm, K., Ruscheweyh, R., & Sacco, S. (2021). Is there a
gender difference in the response to onabotulinumtoxinA in chronic migraine? Pain and
Therapy, 10(2), 1605–1618. https://doi.org/10.1007/s40122-021-00328-y
45. Palacios-Ceña, D., Ordás-Bandera, C., Casas-Limón, J., Pérez-Corrales, J., Güeita-
Rodríguez, J., Arias-Navalón, J. A., & Cuadrado, M. (2023). Real-world experience of
onabotulinumtoxinA treatment in female patients with chronic migraine: A qualitative
study using in-depth interviews. Annals of Medicine, 55(2), 2255215.
https://doi.org/10.1080/07853890.2023.2255215
46. Papetti, L., Frattale, I., Ursitti, F., Sforza, G., Monte, G., Ferilli, M. A. N., Tarantino, S.,
Proietti Checchi, M., & Valeriani, M. (2023). Real-life data on onabotulinumtoxinA for
treatment of chronic migraine in pediatric age. Journal of Clinical Medicine, 12(5), 1802.
https://doi.org/10.3390/jcm12051802
47. Pozo-Rosich, P., Alpuente, A., Silberstein, S. D., & Burstein, R. (2024). Insights from 25
years of onabotulinumtoxinA in migraine—Mechanisms and management. Nature
Reviews Neurology, 20(9), 555–568. https://doi.org/10.1038/s41582-024-01002-5
48. Ray, J., & Raviskanthan, S. (2023). Music medicine to improve the tolerability of
onabotulinumtoxinA injections for chronic migraine. BMJ Neurology Open, 5(2),
e000492. https://doi.org/10.1136/bmjno-2023-000492
49. Rodríguez-Montolio, J., Navarro-Pérez, M. P., Almeida-Zurita, M., & Santos-Lasaosa, S.
(2023). Early wearing-off effect of onabotulinumtoxinA in chronic migraine: A
prospective real-life study. Journal of Clinical Medicine, 12(16), 5360.
https://doi.org/10.3390/jcm12165360
50. Ruşen, E., Hafez, G., & Tunç, Y. (2024). The wear-off phenomenon of repeated
botulinum toxin injection for chronic migraine treatment: A retrospective study. Türk
Nöroloji Dergisi, 30(1), 47–55. https://doi.org/10.55697/tnd.2024.18
51. Sanjay, C., Susie, L., Maha, A., Salwa, K., & Manjit, M. (2023). OnabotulinumtoxinA
for new daily persistent headache and comparison to chronic migraine. Journal of
Neurology, Neurosurgery and Psychiatry, 94(Suppl 1), A27.
https://doi.org/10.1136/JNNP-2023-ABN.82
52. Santoro, A., Fontana, A., Copetti, M., Miscio, A. M., & d’Orsi, G. (2025). Real-world
insights into the effectiveness and tolerability of onabotulinumtoxinA in chronic
migraine: A long-term evaluation of up to 11 years. Toxins, 17(4), 208.
https://doi.org/10.3390/toxins17040208
53. Scuteri, D., Pagliaro, M., Iannacchero, R., Trimboli, M., Lawrence, G. W., Bagetta, G., &
Corasaniti, M. T. (2025). Comparing eptinezumab with onabotulinumtoxinA in the
treatment of chronic migraine: A real-world evidence study. Journal of Headache and
Pain, 26, 159. https://doi.org/10.1186/s10194-025-02106-z
54. Sebastianelli, G., Casillo, F., Di Renzo, A., Abagnale, C., Cioffi, E., Parisi, V., Di
Lorenzo, C., Serrao, M., Pierelli, F., Schoenen, J., & Coppola, G. (2023). Effects of
botulinum toxin type A on the nociceptive and lemniscal somatosensory systems in
chronic migraine. Toxins, 15(1), 76. https://doi.org/10.3390/toxins15010076
55. Shaterian, N., Ghanaatpisheh, A., Abbasi, F., Daniali, S., Jahromi, M. J., Sanie, M. S., &
Abdoli, A. (2022). Botox (onabotulinumtoxinA) for treatment of migraine symptoms: A
systematic review. Pain Research & Management, 2022, 1–15.
https://doi.org/10.1155/2022/3284446
56. Stovner, L. J., Hagen, K., Tronvik, E., Bruvik Gravdahl, G., Burstein, R., & Dodick, D.
W. (2022). FollowTheSutures: Piloting a new way to administer onabotulinumtoxinA for
chronic migraine. Cephalalgia, 42(7), 590–597.
https://doi.org/10.1177/03331024211067775
57. Toni, T., Tamanaha, R., Newman, B., Liang, Y., Lee, J., Carrazana, E., Vajjala, V.,
Viereck, J., & Liow, K. K. (2021). Effectiveness of dual migraine therapy with CGRP
inhibitors and onabotulinumtoxinA injections: Case series. Neurological Sciences,
42(12), 5373–5376. https://doi.org/10.1007/s10072-021-05547-x
58. Torrente, A., Pilati, L., Di Marco, S., Maccora, S., Alonge, P., Vassallo, L., Lupica, A.,
Coppola, S., Camarda, C., Bolognini, N., & Brighina, F. (2022). OnabotulinumtoxinA
modulates visual cortical excitability in chronic migraine: Effects of 12-week treatment.
Toxins, 15(1), 23. https://doi.org/10.3390/toxins15010023
59. Yuan, H., Cohen, F., Driessen, M. T., Krasenbaum, L. J., Ortega, M., Hopkins, M., &
Marmura, M. J. (2024). Real-world effectiveness of add-on fremanezumab in patients
receiving onabotulinumtoxinA for the prevention of chronic migraine. Cephalalgia
Reports, 7. https://doi.org/10.1177/25158163241238448
60. Zandieh, A., & Cutrer, F. M. (2022). OnabotulinumtoxinA in chronic migraine: Is the
response dose dependent? BMC Neurology, 22(1), 218. https://doi.org/10.1186/s12883-
022-02742-x
